Expand ALGS Menu
ALGS MENU

ALGS Latest Press Releases

-- August 6, 2026 --

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results Globe Newswire 8:00 AM

-- July 30, 2026 --

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 Globe Newswire 8:00 AM

-- July 13, 2026 --

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection Globe Newswire 8:00 AM

-- July 6, 2026 --

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection Globe Newswire 4:05 PM

-- May 27, 2026 --

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026 Globe Newswire 2:30 AM

-- May 13, 2026 --

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 Globe Newswire 2:05 AM

-- May 7, 2026 --

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results Globe Newswire 4:05 PM

-- April 30, 2026 --

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 Globe Newswire 4:05 PM

-- April 24, 2026 --

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:00 AM

-- April 16, 2026 --

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection Globe Newswire 6:00 AM

-- April 14, 2026 --

Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes